Cellular Senescence Network (SenNet):Technology Projects (UG3/UH3 Clinical Trial Not Allowed)
ID: 359168Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359168
Timeline
    Description

    The National Institutes of Health (NIH) is announcing a funding opportunity for the Cellular Senescence Network (SenNet): Technology Projects (UG3/UH3 Clinical Trial Not Allowed), aimed at small businesses. This initiative seeks to advance understanding of cellular senescence and its implications for health and disease by developing innovative tools and technologies to identify and characterize senescent cells, ultimately facilitating the creation of senotherapeutic strategies. With an estimated total program funding of $6 million and approximately 15 awards anticipated, interested applicants are encouraged to prepare collaborative proposals ahead of the expected application solicitation, which will be published in October 2025, with a closing date in December 2025. For further inquiries, potential applicants can contact Ajay Pillai at ajay.pillai3@nih.gov or by phone at 301-538-4811.

    Point(s) of Contact
    Ajay Pillai Office of Strategic Coordination, DPCPSI, OD
    (301) 538-4811
    ajay.pillai3@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    Cellular Senescence Network (SenNet): SenNet Data Coordination, Integration and Organizational Center (U24 or UM1)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for the Cellular Senescence Network (SenNet) Data Coordination, Integration and Organizational Center (U24 or UM1) as part of its efforts to advance research on cellular senescence and its implications for health and disease. This initiative aims to understand the biological consequences of senescent cell heterogeneity and to develop senotherapeutic strategies by integrating tissue mapping efforts with data to create comprehensive Atlases of Senescence. The program is critical for identifying tissue-specific senescence markers and enhancing health outcomes, with an estimated total funding of $3.4 million and approximately 25 awards expected. Interested applicants can reach out to Ajay Pillai at ajay.pillai3@nih.gov or by phone at 301.538.4811 for further information, with key deadlines including a synopsis post date on September 12, 2025, and a close date on November 13, 2025.
    Notice of Intent to Publish a Funding Opportunity Announcement for Facilitating Preclinical and Early Phase Human Studies for New Therapeutics (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for facilitating preclinical and early phase human studies for new therapeutics, specifically targeting aging-related conditions. This initiative aims to advance T1 translational aging research, focusing on therapeutics that progress from preclinical stages to first-in-human trials, addressing conditions such as sarcopenia and heart failure with preserved ejection fraction (HFpEF). The funding opportunity, categorized under health-related activities, will utilize the UG3/UH3 Cooperative Agreement mechanism, with an estimated total program funding of $2.5 million. Interested applicants should prepare to submit their applications by fall 2024, with the NOFO expected to be published in summer 2024 and awards anticipated by July 2025.
    Aging Mammalian Tissues In Vitro
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) titled "Aging Mammalian Tissues In Vitro," aimed at soliciting applications for interdisciplinary research focused on developing complex mammalian 3-dimensional (3D) in vitro microphysiological systems (MPS) to model aging processes. The initiative seeks to advance the understanding of aging biology through innovative systems derived primarily from human cells, although nonhuman mammalian cells may be utilized for validation purposes. This funding opportunity is particularly significant as it encourages exploratory research at early stages without requiring preliminary data, fostering collaboration across various disciplines such as stem cell biology, bioengineering, and pharmacology. Interested applicants can reach out to Dr. Tiziana Cogliati at tiziana.cogliati@mail.nih.gov or call 240-397-4596 for further information, with the estimated synopsis posting date set for August 15, 2025, and applications expected to be accepted until October 15, 2025.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects that contribute to the field, although applications are not currently being solicited. With an estimated total program funding of $400,000, interested applicants should prepare for the upcoming Notice of Funding Opportunity (NOFO), with key dates including an estimated synopsis post date of August 1, 2025, and a close date of October 21, 2025. For further inquiries, potential applicants can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator- Initiated Studies (UH3 Clincical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies," aimed at advancing research in regenerative medicine utilizing adult stem cells. This initiative, supported by the 21st Century Cures Act, encourages small businesses to develop collaborative projects, although applications are not currently being solicited. The funding will be provided through a cooperative agreement, with an estimated synopsis posting date of August 1, 2025, and a closing date for applications expected by October 21, 2025. For further inquiries, interested parties can contact Aron Marquitz, Ph.D., at aron.marquitz@nih.gov or by phone at 301-435-1240.
    New NIA Institutional Training Programs for Aging Research
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "New NIA Institutional Training Programs for Aging Research," aimed at developing and expanding a trained workforce in scientific disciplines related to aging research. This grant will support the establishment of new institutional predoctoral and/or postdoctoral training programs in high-priority areas, covering costs such as stipends, tuition, fees, and training-related expenses for selected trainees, while excluding programs focused on Alzheimer's disease and similar initiatives already funded at the applicant institution. Interested small businesses are encouraged to prepare for this opportunity, with an estimated synopsis posting date of October 1, 2025, and a closing date for applications expected by May 25, 2026; for further inquiries, contact Dr. Laura Major at NIATraining@mail.nih.gov or call 301-827-4464.
    Forecast to Publish a Notice of Funding Opportunity for The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Metastasis Research Network (MetNet), specifically targeting research projects under the U01 Clinical Trial Not Allowed funding mechanism. This initiative aims to solicit applications that utilize integrative systems-level approaches to address critical questions in metastasis research, aligning with the ongoing efforts of the MetNet, which focuses on understanding the complex dynamics of metastasis through collaborative research. The anticipated NOFO is expected to be published in Summer 2025, with applications due in Fall 2025, and will support approximately 10 awards, with no cost-sharing or matching requirements. For further inquiries, interested applicants can contact Joanna M. Watson, Ph.D., at watsonjo@mail.nih.gov or by phone at 240-276-6206.
    Notice of Intent to Publish a Funding Opportunity Announcement for NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers, designated as a UG1 Clinical Trial Not Allowed cooperative agreement. This initiative aims to support leadership and expertise in integrating translational science into clinical trials, particularly focusing on multi-center, late-phase treatment trials across various cancer types and patient demographics. The total estimated program funding is $2 million, with an award ceiling of $850,000 and an expected two awards to be made. The Notice of Funding Opportunity (NOFO) is anticipated to be published in Fall 2024, with applications due in late February 2025, and awards expected to be announced by March 1, 2026. Interested applicants should prepare their proposals accordingly.
    Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for Complex Integrated Multi-Component Projects in Aging Research, designated as a U19 Clinical Trial Optional grant. This initiative aims to support large-scale, multidisciplinary research projects that address common questions related to aging, encouraging collaboration among investigators from various institutions. The program is particularly significant as it seeks to advance scientific knowledge in aging while addressing health disparities and promoting innovative research approaches. Interested applicants, including higher education institutions, nonprofits, and government agencies, can submit proposals until September 25, 2025, with a maximum project period of five years. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-213.html.